Skip to main content
SpringerLink
Log in

Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension

  • Chapter
  • First Online:
Pulmonary Hypertension

Part of the book series: Respiratory Medicine ((RM))

  • 939 Accesses

Abstract

Parenteral prostacyclin therapy is first-line for Group 1 pulmonary arterial hypertension patients with severely limited functional status. There are two current pharmacologic options in this realm, intravenous epoprostenol and intravenous or subcutaneous treprostinil. In this chapter, we will discuss similarities and differences between the two formulations, present practical knowledge for prescribing these therapies, and outline the current indications and the data supporting those recommendations. We will dissect the components of the clinical trials that exist in this realm and controversies therein. Lastly, we will discuss the timing of initiation of therapy, as well as patient-focused concerns and challenges with parenteral therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75. https://doi.org/10.1183/13993003.01032-2015.

    Article  CAS  PubMed  Google Scholar 

  2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619. https://doi.org/10.1016/j.jacc.2009.01.004.

    Article  PubMed  Google Scholar 

  3. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A–10A.

    Article  CAS  PubMed  Google Scholar 

  4. Christman BW, CD MP, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70–5. https://doi.org/10.1056/NEJM199207093270202.

    Article  CAS  PubMed  Google Scholar 

  5. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31:891–901. https://doi.org/10.1183/09031936.00097107.

    Article  CAS  PubMed  Google Scholar 

  6. Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med. 2001;138:287–97. https://doi.org/10.1067/mlc.2001.119329.

    Article  CAS  PubMed  Google Scholar 

  7. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111–7. https://doi.org/10.1056/NEJM199701093360207.

    Article  CAS  PubMed  Google Scholar 

  8. Schror K, Weber AA. Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl. 1997;48:63–91.

    CAS  PubMed  Google Scholar 

  9. Sinzinger H, Fitscha P, Kritz H. Antimitotic actions of vasodilatory prostaglandins–clinical aspects. Agents Actions Suppl. 1997;48:92–106.

    CAS  PubMed  Google Scholar 

  10. Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182:1161–70. https://doi.org/10.1164/rccm.201001-0011OC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Falcetti E, Flavell DM, Staels B, et al. IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues. Biochem Biophys Res Commun. 2007;360:821–7. https://doi.org/10.1016/j.bbrc.2007.06.135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Crutchley DJ, Hirsh MJ. The stable prostacyclin analog, iloprost, and prostaglandin E1 inhibit monocyte procoagulant activity in vitro. Blood. 1991;78:382–6.

    Article  CAS  PubMed  Google Scholar 

  13. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 1997;96:2782–4.

    Article  CAS  PubMed  Google Scholar 

  14. Fontana M, Olschewski H, Olschewski A, et al. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol. 2007;151:779–86. https://doi.org/10.1038/sj.bjp.0707300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Armstrong JM, Chapple D, Dusting GJ, et al. Cardiovascular actions of prostacyclin (PCI2) in chloralose anaesthetized dogs [proceedings]. Br J Pharmacol. 1977;61:136P.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Metsa-Ketela T. Cyclic AMP-dependent and -independent effects of prostaglandins on the contraction-relaxation cycle of spontaneously beating isolated rat atria. Acta Physiol Scand. 1981;112:481–5. https://doi.org/10.1111/j.1748-1716.1981.tb06847.x.

    Article  CAS  PubMed  Google Scholar 

  17. Fassina G, Tessari F, Dorigo P. Positive inotropic effect of a stable analogue of PGI2 and of PGI2 on isolated Guinea pig atria. Mechanism of action. Pharmacol Res Commun. 1983;15:735–49.

    Article  CAS  PubMed  Google Scholar 

  18. Karmazyn M. Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts. Am J Physiol. 1986;251:H133–40. https://doi.org/10.1152/ajpheart.1986.251.1.H133.

    Article  CAS  PubMed  Google Scholar 

  19. Kerbaul F, Brimioulle S, Rondelet B, et al. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med. 2007;175:846–50. https://doi.org/10.1164/rccm.200611-1615OC.

    Article  CAS  PubMed  Google Scholar 

  20. Montalescot G, Drobinski G, Meurin P, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol. 1998;82:749–55.

    Article  CAS  PubMed  Google Scholar 

  21. Shinmura K, Tamaki K, Sato T, et al. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol Heart Circ Physiol. 2005;288:H2093–101. https://doi.org/10.1152/ajpheart.01003.2004.

    Article  CAS  PubMed  Google Scholar 

  22. Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019:53. https://doi.org/10.1183/13993003.01889-2018.

  23. Gryglewski RJ, Szczeklik A, Nizankowski R. Anti-platelet action of intravenous infusion of prostacyclin in man. Thromb Res. 1978;13:153–63.

    Article  CAS  PubMed  Google Scholar 

  24. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1:1046–7.

    Article  CAS  PubMed  Google Scholar 

  25. Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66:334–8.

    Article  CAS  PubMed  Google Scholar 

  26. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301. https://doi.org/10.1056/NEJM199602013340504.

    Article  CAS  PubMed  Google Scholar 

  27. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409–15.

    Article  CAS  PubMed  Google Scholar 

  28. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485–91.

    Article  CAS  PubMed  Google Scholar 

  29. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425–34.

    Article  CAS  PubMed  Google Scholar 

  30. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477–82.

    Article  CAS  PubMed  Google Scholar 

  31. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780–8.

    Article  CAS  PubMed  Google Scholar 

  32. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997;30:343–9. https://doi.org/10.1016/s0735-1097(97)00187-3.

    Article  CAS  PubMed  Google Scholar 

  33. Bergot E, Sitbon O, Cottin V, et al. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. Int J Cardiol. 2014;172:561–7. https://doi.org/10.1016/j.ijcard.2013.12.313.

    Article  PubMed  Google Scholar 

  34. Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med. 2003;167:580–6. https://doi.org/10.1164/rccm.200204-333OC.

    Article  PubMed  Google Scholar 

  35. Veletri (epoprostenol) for injection. [package insert]. San Francisco: Actelion Pharmaceuticals US, Inc; 2012.

    Google Scholar 

  36. Flolan (epoprostenol sodium) for Injection. [package insert]. Research Triangle Park, NC: GlaxoSmithKline. 2008.

    Google Scholar 

  37. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J. 1999;13:1351–6.

    Article  CAS  PubMed  Google Scholar 

  38. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007; 132: 757-763. https://doi.org/10.1378/chest.06-2118.

  39. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1184–7.

    Article  CAS  PubMed  Google Scholar 

  40. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338:273–7. https://doi.org/10.1056/NEJM199801293380501.

    Article  CAS  PubMed  Google Scholar 

  41. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126:420–7. https://doi.org/10.1378/chest.126.2.420.

    Article  CAS  PubMed  Google Scholar 

  42. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129:1636–43. https://doi.org/10.1378/chest.129.6.1636.

    Article  CAS  PubMed  Google Scholar 

  43. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–4. https://doi.org/10.1164/ajrccm.165.6.2106079.

    Article  PubMed  Google Scholar 

  44. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487–92. https://doi.org/10.1164/ajrccm.161.2.9906015.

    Article  CAS  PubMed  Google Scholar 

  45. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28:1195–203. https://doi.org/10.1183/09031936.06.00044406.

    Article  CAS  PubMed  Google Scholar 

  46. Vachiery JL, Hill N, Zwicke D, et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest. 2002;121:1561–5. https://doi.org/10.1378/chest.121.5.1561.

    Article  CAS  PubMed  Google Scholar 

  47. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44:209–14.

    Article  CAS  PubMed  Google Scholar 

  48. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172:1586–9. https://doi.org/10.1164/rccm.200505-766OC.

    Article  PubMed  Google Scholar 

  49. Remodulin (treprostinil). [package insert] Research Triangle Park, NC: United Therapeutics Corp; 2014.

    Google Scholar 

  50. Yorke J, Corris P, Gaine S, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014;43:1106–13. https://doi.org/10.1183/09031936.00127113.

    Article  PubMed  Google Scholar 

  51. McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006;15:103–15. https://doi.org/10.1007/s11136-005-3513-4.

    Article  CAS  PubMed  Google Scholar 

  52. McCollister D, Shaffer S, Badesch DB, et al. Development of the pulmonary arterial hypertension-symptoms and impact (PAH-SYMPACT(R)) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res. 2016;17:72. https://doi.org/10.1186/s12931-016-0388-6.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Shah MR, Hasselblad V, Gheorghiade M, et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2001;88:987–93.

    Article  CAS  PubMed  Google Scholar 

  54. Enfield K, Gammon S, Floyd J, et al. Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2010;30:195–202. https://doi.org/10.1097/HCR.0b013e3181c565e4.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174:803–9. https://doi.org/10.1164/rccm.200604-488OC.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Chua R, Keogh AM, Byth K, et al. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J. 2006;36:705–10. https://doi.org/10.1111/j.1445-5994.2006.01169.x.

    Article  CAS  PubMed  Google Scholar 

  57. Camarri B, Eastwood PR, Cecins NM, et al. Six minute walk distance in healthy subjects aged 55-75 years. Respir Med. 2006;100:658–65. https://doi.org/10.1016/j.rmed.2005.08.003.

    Article  PubMed  Google Scholar 

  58. Gibbons WJ, Fruchter N, Sloan S, et al. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil. 2001;21:87–93.

    Article  CAS  PubMed  Google Scholar 

  59. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999;14:270–4.

    Article  CAS  PubMed  Google Scholar 

  60. Lee WT, Peacock AJ, Johnson MK. The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension. Eur Respir J. 2010;36:1294–301. https://doi.org/10.1183/09031936.00155009.

    Article  PubMed  Google Scholar 

  61. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119. https://doi.org/10.1093/eurheartj/ehv317.

    Article  PubMed  Google Scholar 

  62. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007;153:1037–47. https://doi.org/10.1016/j.ahj.2007.02.037.

    Article  PubMed  Google Scholar 

  63. Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010;159:245–57. https://doi.org/10.1016/j.ahj.2009.11.028.

    Article  CAS  PubMed  Google Scholar 

  64. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60:1192–201. https://doi.org/10.1016/j.jacc.2012.01.083.

    Article  PubMed  Google Scholar 

  65. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30:632–43. https://doi.org/10.1016/j.healun.2010.11.009.

    Article  PubMed  Google Scholar 

  66. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521–30.

    Article  PubMed  Google Scholar 

  67. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903. https://doi.org/10.1056/NEJMoa012212.

    Article  CAS  PubMed  Google Scholar 

  68. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S97–107. https://doi.org/10.1016/j.jacc.2009.04.007.

    Article  PubMed  Google Scholar 

  69. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29:137–49. https://doi.org/10.1016/j.healun.2009.09.005.

    Article  PubMed  Google Scholar 

  70. Helman DL Jr, Brown AW, Jackson JL, et al. Analyzing the short-term effect of placebo therapy in pulmonary arterial hypertension: potential implications for the design of future clinical trials. Chest. 2007;132:764–72. https://doi.org/10.1378/chest.07-0236.

    Article  PubMed  Google Scholar 

  71. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–502.

    Article  CAS  PubMed  Google Scholar 

  72. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–25.

    Article  CAS  PubMed  Google Scholar 

  73. Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019:53. https://doi.org/10.1183/13993003.01908-2018.

  74. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–33. https://doi.org/10.1056/NEJMoa1503184.

    Article  CAS  PubMed  Google Scholar 

  75. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18. https://doi.org/10.1056/NEJMoa1213917.

    Article  CAS  PubMed  Google Scholar 

  76. Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834–44. https://doi.org/10.1056/NEJMoa1413687.

    Article  CAS  PubMed  Google Scholar 

  77. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–54. https://doi.org/10.1016/j.jacc.2009.04.012.

    Article  PubMed  Google Scholar 

  78. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–23.

    Article  CAS  PubMed  Google Scholar 

  79. Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012;8:413–25. https://doi.org/10.1016/j.hfc.2012.04.001.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Humbert M, Sanchez O, Fartoukh M, et al. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). Chest. 1998;114:80S–2S. https://doi.org/10.1378/chest.114.1_supplement.80s.

    Article  CAS  PubMed  Google Scholar 

  81. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129:683–8. https://doi.org/10.1378/chest.129.3.683.

    Article  CAS  PubMed  Google Scholar 

  82. Vegh J, Hegedus I, Szegedi G, et al. Diastolic function of the heart in mixed connective tissue disease. Clin Rheumatol. 2007;26:176–81. https://doi.org/10.1007/s10067-006-0257-7.

    Article  PubMed  Google Scholar 

  83. Blasco Mata LM, Acha Salazar O, Gonzalez-Fernandez CR, et al. Systemic lupus erythematosus and systemic autoimmune connective tissue disorders behind recurrent diastolic heart failure. Clin Dev Immunol. 2012;2012:831434. https://doi.org/10.1155/2012/831434.

    Article  PubMed  Google Scholar 

  84. Tennoe AH, Murbraech K, Andreassen JC, et al. Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis. J Am Coll Cardiol. 2018;72:1804–13. https://doi.org/10.1016/j.jacc.2018.07.068.

    Article  PubMed  Google Scholar 

  85. Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 1998;113:237–40. https://doi.org/10.1378/chest.113.1.237.

    Article  CAS  PubMed  Google Scholar 

  86. Farber HW, Graven KK, Kokolski G, et al. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol. 1999;26:1195–6.

    CAS  PubMed  Google Scholar 

  87. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs. 2008;68:1049–66. https://doi.org/10.2165/00003495-200868080-00004.

    Article  CAS  PubMed  Google Scholar 

  88. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858–65.

    Article  CAS  PubMed  Google Scholar 

  89. Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91:632–5.

    Article  CAS  PubMed  Google Scholar 

  90. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363:1461–8. https://doi.org/10.1016/S0140-6736(04)16107-2.

    Article  PubMed  Google Scholar 

  91. Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl. 2005;11:1107–11. https://doi.org/10.1002/lt.20459.

    Article  PubMed  Google Scholar 

  92. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation. 1997;63:604–6.

    Article  CAS  PubMed  Google Scholar 

  93. Plotkin JS, Kuo PC, Rubin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation. 1998;65:457–9.

    Article  CAS  PubMed  Google Scholar 

  94. Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641–8. https://doi.org/10.1002/hep.510300307.

    Article  CAS  PubMed  Google Scholar 

  95. Noor MT, Manoria P. Immune dysfunction in cirrhosis. J Clin Transl Hepatol. 2017;5:50–8. https://doi.org/10.14218/JCTH.2016.00056.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Moller S, Bendtsen F, Henriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest. 2001;61:421–9.

    Article  CAS  PubMed  Google Scholar 

  97. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128–37. https://doi.org/10.1161/CIRCULATIONAHA.111.079921.

    Article  CAS  PubMed  Google Scholar 

  98. Coplan NL, Shimony RY, Ioachim HL, et al. Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med. 1990;89:96–9.

    Article  CAS  PubMed  Google Scholar 

  99. Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest. 1991;100:1268–71. https://doi.org/10.1378/chest.100.5.1268.

    Article  CAS  PubMed  Google Scholar 

  100. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162:1846–50. https://doi.org/10.1164/ajrccm.162.5.2004042.

    Article  CAS  PubMed  Google Scholar 

  101. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003:167, 1433–1439. https://doi.org/10.1164/rccm.200204-330OC.

  102. Cea-Calvo L, Escribano Subias P, Tello de Menesses R, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev Esp Cardiol. 2003;56:421–5.

    Article  PubMed  Google Scholar 

  103. Davis LL, deBoisblanc BP, Glynn CE, et al. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest. 1995;108:1754–6. https://doi.org/10.1378/chest.108.6.1754.

    Article  CAS  PubMed  Google Scholar 

  104. Correa Rde A, Moreira MV, Saraiva JM, et al. Treatment of schistosomiasis-associated pulmonary hypertension. J Bras Pneumol. 2011;37:272–6.

    Article  PubMed  Google Scholar 

  105. Fernandes C, Dias BA, Jardim CVP, et al. The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. Chest. 2012;141:923–8. https://doi.org/10.1378/chest.11-0483.

    Article  PubMed  Google Scholar 

  106. Papamatheakis DG, Mocumbi AO, Kim NH, et al. Schistosomiasis-associated pulmonary hypertension. Pulm Circ. 2014;4:596–611. https://doi.org/10.1086/678507.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003;76:1457–62; discussion 1462–54. 2003/11/07

    Article  PubMed  Google Scholar 

  108. Hartz RS, Byrne JG, Levitsky S, et al. Predictors of mortality in pulmonary thromboendarterectomy. Ann Thorac Surg. 1996;62:1255–9; discussion 1259-1260. 1996/11/01. https://doi.org/10.1016/0003-4975(96)00460-2.

    Article  CAS  PubMed  Google Scholar 

  109. Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest. 2003;123:338–43. https://doi.org/10.1378/chest.123.2.338.

    Article  CAS  PubMed  Google Scholar 

  110. Bresser P, Fedullo PF, Auger WR, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23:595–600.

    Article  CAS  PubMed  Google Scholar 

  111. Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009;120:1248–54. https://doi.org/10.1161/CIRCULATIONAHA.109.865881.

    Article  PubMed  Google Scholar 

  112. Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation. 2016;133:859–71. https://doi.org/10.1161/CIRCULATIONAHA.115.016522.

    Article  CAS  PubMed  Google Scholar 

  113. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141:702–10. https://doi.org/10.1016/j.jtcvs.2010.11.024.

    Article  PubMed  Google Scholar 

  114. Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med. 2019;7:239–48. https://doi.org/10.1016/S2213-2600(18)30367-9.

    Article  CAS  PubMed  Google Scholar 

  115. Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2007;26:357–62. https://doi.org/10.1016/j.healun.2006.12.014.

    Article  PubMed  Google Scholar 

  116. Scelsi L, Ghio S, Campana C, et al. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. Ital Heart J. 2004;5:618–23.

    PubMed  Google Scholar 

  117. Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J. 2012;39:1520–33. https://doi.org/10.1183/09031936.00175511.

    Article  PubMed  Google Scholar 

  118. Bonham CA, Oldham JM, Gomberg-Maitland M, et al. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest. 2015;148:1055–62. https://doi.org/10.1378/chest.14-2546.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: the REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019. https://doi.org/10.1016/j.chest.2019.02.004.

  120. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164–72. https://doi.org/10.1161/CIRCULATIONAHA.109.898122.

    Article  PubMed  Google Scholar 

  121. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141:354–62. https://doi.org/10.1378/chest.11-0676.

    Article  PubMed  Google Scholar 

  122. Halliday SJ, Xu M, Thayer TE, et al. Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. Pulm Circ. 2018;8:2045894018800544. https://doi.org/10.1177/2045894018800544.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Sikirica M, Iorga SR, Bancroft T, et al. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676. https://doi.org/10.1186/s12913-014-0676-0.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Zhai Z, Zhou X, Zhang S, et al. The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey. Medicine (Baltimore). 2017;96:e6783. https://doi.org/10.1097/MD.0000000000006783.

    Article  Google Scholar 

  125. FDA U. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https://www.fdagov/downloads/Drugs/Guidances/UCM193282pdf.

  126. Macitentan (Opsumit): For Long-Term Treatment of Pulmonary Arterial Hypertension. Ottawa (ON), 2015.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    Jessica H. Huston

  2. Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    Anna R. Hemnes

Authors
  1. Jessica H. Huston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna R. Hemnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica H. Huston .

Editor information

Editors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Department of Medicine Pulmonary Hypertension Program University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    H. James Ford

  2. Department of Pulmonary, and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA

    Gustavo A. Heresi

  3. Division of Pulmonary Allergy and Critical Care Medicine, Pittsburgh Heart, Lung Blood and Vascular Medicine Institute University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Michael G. Risbano

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Huston, J.H., Hemnes, A.R. (2020). Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension. In: Ford, H.J., Heresi, G.A., Risbano, M.G. (eds) Pulmonary Hypertension. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-52787-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52787-7_10

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-52786-0

  • Online ISBN: 978-3-030-52787-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation